levobupivacaine hcl
(S)-(-)-Bupivacaine Hydrochloride
CAS: 27262-48-2
Molecular Formula: C18H29ClN2O
levobupivacaine hcl - Names and Identifiers
levobupivacaine hcl - Physico-chemical Properties
| Molecular Formula | C18H29ClN2O |
| Molar Mass | 324.89 |
| Melting Point | 254°C (dec.)(lit.) |
| Boling Point | 423.4°C at 760 mmHg |
| Specific Rotation(α) | -12.5 º (c=2, water) |
| Flash Point | 209.9°C |
| Solubility | H2O: soluble20mg/mL, clear |
| Vapor Presure | 2.24E-07mmHg at 25°C |
| Appearance | powder |
| Color | white to beige |
| Storage Condition | 2-8°C |
| In vitro study | Levobupivacaine is a local anesthetic of the amide type. Levobupivacaine works by blocking voltage-sensitive ion channels in the cell membrane of neurons, preventing the conduction of nerve impulses. By interfering with the opening of sodium channels, a local reversible anesthetic effect is produced, which inhibits the conduction of nerve action potentials including sensory, myokinetic and sympathetic activity. Levobupivacaine replaces 3 H-BTX in the sodium ion channel of rat brain synaptosomes with an IC50 of 2.9 μm and a Hill coefficient of 1.2. When the cell membrane was at -80 mV,-70 mV,-60 mV or -100 mV, levobupuvacaine showed tonic inhibition of sodium ion channels in GH3 cells, IC50s were 132.1,37.6, respectively, 21.6 and 264 μm. Levobupuvacaine inhibits the action potential of isolated axons in vitro. Levobupivacaine (1mm) inhibited the amplitude and maximum growth velocity (dV/dt max) of action potentials in crayfish giant axons with values of 88 and 81, respectively, after 15 min of perfusion. Levobupivacaine also shows activity on cardiac ion channels. In isolated ventricular myocytes, the apparent affinity of Levobupivacaine for sodium channels in the inactivated state was 4.8 μm and the calculated KD was 39 μm. Inhibition of the cardiac delayed rectifier potassium channel (hKv1.5), the steady-state blockade by Levobupivacaine (20 μm) was 31%, and the calculated KD was 27.3 μm. Levobupivacaine may also inhibit cardiac calcium channels. 10 μm Levobupivacaine reduced the contractility of guinea pig papillary muscles by 50%. |
| In vivo study | Levobupuvacaine and bupivacaine have similar nerve blocking efficacy. Levobupivacaine, at a dose of 0.125, inhibited motor muscle and pain responses with a maximum% MPE of 99 and 68, respectively, and inhibit the duration of motor muscle and pain response deficits after sciatic nerve block (60 and 30, respectively). |
levobupivacaine hcl - Risk and Safety
| Risk Codes | R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed. R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. R28 - Very Toxic if swallowed |
| Safety Description | S22 - Do not breathe dust. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37 - Wear suitable protective clothing and gloves. S53 - Avoid exposure - obtain special instructions before use. |
| UN IDs | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS | TK6125000 |
